Cancer Cell Line Authentication: STR Profiling, Mycoplasma Testing & Quality Control

Cell line misidentification and cross-contamination is one of the most persistent and damaging problems in biomedical research. Studies estimate that 15–20% of cell lines in active use are misidentified, leading to irreproducible results, retracted publications, and wasted research funding.

Practical Guide

STR (short tandem repeat) profiling is the gold standard for human cell line authentication. It compares the STR profile of your working cell line against reference profiles in databases (ATCC, DSMZ, Cellosaurus). All journals in the ICJME network now require STR authentication data for cell line-based studies.

Mycoplasma contamination affects an estimated 5–35% of cell cultures worldwide. Mycoplasma alters gene expression, cell growth, metabolism, and immune responses without visible signs of contamination. Detection by PCR-based assay (targeting the 16S rRNA gene) should be performed monthly or before any critical experiment.

Cross-contamination prevention: use single-line hoods (one cell line at a time), maintain frozen stocks at early passage, never share media between cell lines, and authenticate at regular intervals (every 2–3 months or whenever cells behave unexpectedly).

abinScience offers 81 stable cell lines, each authenticated by STR profiling and confirmed mycoplasma-negative at the time of banking. For custom cell line development (target-overexpressing lines, reporter lines, knockout lines), AtaGenix provides a complete CRO service from gene to banked clone in ~12 weeks. Cell line authentication is a critical step in the stable cell line development workflow (Stage 6: Banking & Characterization).

Authenticated cell lines support reproducible results across all downstream applications including Western blot, flow cytometry, and IHC validation — ensuring that antibody performance data is attributable to the correct cell type.

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

All products are for research use only. For technical support, contact order@abinscience.com.